Skip to main content

Translational Molecular Pathology

Our group aims to unravel the molecular mechanisms of cancer progression and metastasis to identify new diagnostic, prognostic and therapeutic targets in cancer. By combining the knowledge and availability of human tumors in the Pathology department with the expertise of the basic molecular cell biology research group, we focus on:

  • Understanding: the molecular mechanisms underlying clonal cooperation and intercellular communication in heterogeneous tumors.
  • The role of MNK kinases in cellular stress resistance.
  • The role of ITGB3 in intercellular communication via extracellular vesicles in cancer metastasis (Santiago Ramon y Cajal).
  • The role of direct cell-cell communication via gap junctions and intercellular protrusions in cancer (Trond Aasen)
  • The malignant transition of Plexiform Neurofibromas (Cleofe Romagosa).

Team

Santiago Ramon y Cajal Agüeras

Santiago Ramon y Cajal Agüeras

Head of group
Translational Molecular Pathology
Read more
Stefan Hummer

Stefan Hummer

Main researcher
Translational Molecular Pathology
Read more
Trond Aasen

Trond Aasen

Main researcher
Translational Molecular Pathology
Read more
Ximena Garcia Torres

Ximena Garcia Torres

Administration and Management
Translational Molecular Pathology
Read more
Santiago Ramon y Cajal Agüeras

Santiago Ramon y Cajal Agüeras

Head of group
Translational Molecular Pathology
Read more
Stefan Hummer

Stefan Hummer

Main researcher
Translational Molecular Pathology
Read more
Trond Aasen

Trond Aasen

Main researcher
Translational Molecular Pathology
Read more
Ximena Garcia Torres

Ximena Garcia Torres

Administration and Management
Translational Molecular Pathology
Read more

Projects

ScreenEC, validació d'una eina de triatge no invasiu en càncer d'endometri

IP: Eva Colas Ortega
Collaborators: Vicente Bebia Conesa, Francesc Xavier Serra Marin, Josep Castellví Vives, Silvia Cabrera Diaz, Antonio Gil Moreno, Marta Rebull Santamaria, Ana Luzarraga Aznar, Irene De la Calle Fuentes, Lourdes Elena Salazar Huayna
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 99946
Reference: SLT036/24/000059
Duration: 21/12/2024 - 31/12/2026

The MNK inhibitor EB1: a novel opportunity to combat therapy resistance in cancer treatment

IP: Santiago Ramon y Cajal Agüeras
Collaborators: Inés de Torres Ramirez, Sara Garcia Ortega, Elena Muro Blanc, Marta Cano Galietero, Vicente Peg Camara, Stefan Hummer
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 149347
Reference: 2024 PROD 00056
Duration: 02/12/2024 - 01/06/2026

Synthetic Data Generation Framework for Integrated Validation of Use Cases and AI Healthcare Applications

IP: Manuel Escobar Amores
Collaborators: Santiago Ramon y Cajal Agüeras, Aitor Rodriguez Martinez, Javier Hernandez Losa, Sonia Borao Arriazu
Funding agency: EUROPEAN COMMISSION
Funding: 163125
Reference: SYNTHIA_M.ESCOBAR_HE-JU-IHI_2023
Duration: 01/09/2024 - 31/08/2029

Unlocking DCIS lesions progression to prevent women overtreatment and improving their sexual and reproductive health impact

IP: Vicente Peg Camara
Collaborators: Victoria Reyes López
Funding agency: Fundació La Marató de TV3
Funding: 59681.19
Reference: 202424-30
Duration: 10/03/2025 - 09/03/2028

Blog

News

The ten groups within the Cancer Area combine basic, translational and clinical research to identify new targets, biomarkers and therapeutic strategies

The grants promote new therapeutic strategies and diagnostic tools in highly complex tumors such as glioblastoma, triple-negative breast cancer, and endometrial cancer.

The Department of Health of the Generalitat de Catalunya grants subsidies for carrying out validation tests on innovative projects in the field of health that are in the early stages of development.

Rates

Check the current rates for the services offered by the Translational Molecular Pathology research group.

Icona fitxers

Current Rates

PDF 0.25 MB

Icona fitxers

Rates Anatomia Patologica VHIR 2021

PDF 0.22 MB